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Orthopaedic implants, such as joint prostheses and internal
fracture-fixation devices, are increasingly used. In contrast to
transplants, such foreign bodies are accepted by the organism
without immunosuppression. Nevertheless, each type of
implant increases the risk of local infection [1]. Whereas bio-
mechanical aspects of internal devices have steadily improved,
the high susceptibility to infection remains a problem. Despite
preventive measures regarding infection control and antibiotic
prophylaxis, implant-associated infections still occur. Such
infections are caused by surface-adhering microorganisms
forming a biofilm. Bacteria colonizing an implanted non-living
surface persist as aggregated microbial cells surrounded by a
polymeric self-produced matrix containing host components
[2]. Microbial aggregates resist not only host defence mecha-
nisms, but also most antibiotics [1–3]. During the last two
decades, a paradigm shift regarding treatment concepts has
been observed. According to the classical view, implants have
to be removed for complete eradication of biofilm bacteria.
According to novel concepts, this dogma is outdated, at least
in a significant number of cases. After correct microbiological
diagnosis, and if proper antibiotics are rapidly administered,
many orthopaedic devices can be kept in place after thorough
debridement surgery [4].
In this themed section of CMI, three unresolved issues
regarding orthopaedic biofilm infections are covered. First, it
is still not clear whether the type of material plays a crucial
role regarding the propensity for infection. Second, the role of
molecular diagnostics is not yet established for routine diagno-
sis of implant-associated bone infection. Third, there are still
many open questions regarding antimicrobial therapy of such
infections, because large controlled clinical trials are missing.
For obvious reasons, companies developing orthopaedic
devices are more interested in biomechanical research than
in issues regarding prevention of infection. Periprosthetic
joint infection occurs not only during implantation, but
throughout life by the haematogenous route [5]. Thus, peri-
operative antibiotics protect only during a minimal period at
risk. Therefore, knowledge about the influence of biomateri-
als on the propensity for infection is clinically relevant. Roch-
ford et al. [6] from the AO Foundation Research Institute
(Davos, Switzerland) reviewed this question. They report the
interaction of different materials in vivo and in animal models.
However, clinical data showing a reproducible and distinct
propensity of different biomaterials to infection are missing.
It is conceivable that proteins (e.g. fibronectin, fibrinogen or
vitronectin) covering the material immediately after insertion
in the organism are more important for bacterial adhesion
than the material itself [7].
In about 5–15% of patients with periprosthetic joint infec-
tion, no microorganism can be detected. In more than half of
the cases, patients received previous antibiotics [8]. Because
correct long-term antimicrobial therapy depends on the iden-
tification of the correct microorganism, more sensitive diag-
nostic methods are needed. Unfortunately, with molecular
methods no comprehensive susceptibility pattern is available.
Therefore, these tests will not replace microbiological culture
techniques in the near future. Broad-range PCR has two major
drawbacks when used in patients with periprosthetic joint
infection. First, its sensitivity is low and second, polymicrobial
infection is difficult to detect with broad-range PCR targeting
the 16S rRNA sequence without separating the amplification
products by cloning or using gradient gel electrophoresis. Le´vy
& Fenollar [9] reviewed the role of molecular diagnostics in
implant-associated bone and joint infection. Because the
efficiency of these methods heavily depends on the correct
technique, these experienced authors present crucial pre-ana-
lytical and analytical aspects of the entire process. They con-
clude that molecular techniques should not replace
conventional culture, but mainly be used in culture-negative
cases. In the near future, not only broad-range PCR followed
by sequencing, but also real-time multiplex PCR assays with
appropriate primers will be available. For the time being, com-
mercially available multiplex PCR tests are not yet ideal,
because they are not developed for use in patients with peri-
prosthetic joint infection, and hence, lack relevant primers.
Antimicrobial therapy of implant-associated infection is
mainly based on expert opinions. Guidelines based on con-
trolled studies are missing. There are still many open ques-
tions, for example regarding the need for initial intravenous
therapy, the importance of bone penetration, and the role of
rifampin in non-staphylococcal grampositive microorganisms.
Staphylococci are the most frequent microorganisms causing
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bone and joint infection. Linezolid and daptomycin are antimi-
crobial agents with activity on resistant gram-positive microor-
ganisms. Unfortunately, both substances are not yet approved
for use in bone and joint infection. Novel antibiotics are gener-
ally initially approved for frequent indications such as skin and
soft tissue infections, lower respiratory tract infections and
bacteraemia. Therefore, after introduction of a novel antibiotic
to the market, several years of off-label use are required in
order to get enough published data for the evaluation of these
drugs in bone and joint infection. These therapeutic questions
are reviewed in the article by Sendi & Zimmerli [10].
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